published_date,market,entry_time,exit_time,ticker,direction,shares,entry_price,exit_price,target_price,stop_price,hit_target,hit_stop,pnl,pnl_pct,capital_after,news_event,predicted_move,actual_move,link
2024-12-30 08:00:00+00:00,pre_market,2024-12-30 09:30:00+00:00,2024-12-31 08:00:00+00:00,EVAX,LONG,150,5.300000190734863,5.273500189781189,5.353000192642212,5.273500189781189,False,True,-3.9750001430510995,-0.49687501788138744,9996.024999856949,corporate_action,-0.06602477148422325,-8.018871234718494,https://www.globenewswire.com/news-release/2024/12/30/3002643/0/en/Evaxion-announces-plan-to-implement-ADS-ratio-change.html
2024-12-30 08:00:00+00:00,pre_market,2024-12-30 09:30:00+00:00,2024-12-31 08:00:00+00:00,RAD.AX,LONG,34768,0.023000000044703484,0.02323000004515052,0.02323000004515052,0.022885000044479967,True,False,7.996640015542541,0.999977493010594,10004.021639872492,partnerships,1.1366492725954926,13.043480373510564,https://www.globenewswire.com/news-release/2024/12/30/3002629/0/en/Radiopharm-Announces-Strategic-Co-Development-Partnership-with-Lantheus-for-Australia.html
2024-12-30 09:00:00+00:00,pre_market,2024-12-30 09:30:00+00:00,2024-12-31 09:00:00+00:00,RENB,LONG,872,0.9169999957084656,0.9124149957299232,0.9261699956655502,0.9124149957299232,False,True,-3.9981199812889177,-0.4995640909744019,10000.023519891203,management_changes,-0.1531209497909663,-3.3805908685813777,https://www.globenewswire.com/news-release/2024/12/30/3002711/0/en/Renovaro-Inc-Appoints-Maurice-van-Tilburg-to-Lead-GEDi-Cube-BV.html
2024-12-30 09:00:00+00:00,pre_market,2024-12-30 09:30:00+00:00,2024-12-31 09:00:00+00:00,SCLX,LONG,2051,0.38999998569488525,0.3938999855518341,0.3938999855518341,0.3880499857664108,True,False,7.998899706602056,0.9998601116651524,10008.022419597804,dividend_reports_and_estimates,0.13800166206489103,2.5641078544558447,https://www.globenewswire.com/news-release/2024/12/30/3002700/0/en/Scilex-Holding-Company-Announces-Change-in-Record-Date-for-its-Previously-Announced-Dividend-of-Preferred-Stock-Exchangeable-for-up-to-10-of-Scilex-s-Ownership-Interest-in-Semnur-P.html
2025-01-02 07:00:00+00:00,pre_market,2025-01-02 09:30:00+00:00,2025-01-03 07:00:00+00:00,IMCR,LONG,27,29.5,29.5,29.795,29.3525,False,False,0.0,0.0,10008.022419597804,management_changes,-0.1741297459308459,0.0,https://www.globenewswire.com/news-release/2025/01/02/3003442/0/en/Immunocore-appoints-Travis-Coy-previously-a-Non-Executive-Director-as-its-EVP-Chief-Financial-Officer-and-Head-of-Corporate-Development.html
2025-01-02 09:15:00+00:00,pre_market,2025-01-02 09:30:00+00:00,2025-01-03 09:15:00+00:00,CAPR,SHORT,58,13.800000190734863,13.869000191688537,13.662000188827514,13.869000191688537,False,True,-4.002000055313065,-0.4998490070671093,10004.020419542492,regulatory_filings,-0.5387662960308597,1.5942048115080016,https://www.globenewswire.com/news-release/2025/01/02/3003570/0/en/Capricor-Therapeutics-Completes-Submission-of-Biologics-License-Application-to-the-U-S-FDA-for-Deramiocel-for-the-Treatment-of-Duchenne-Muscular-Dystrophy.html
2025-01-03 08:00:00+00:00,pre_market,2025-01-03 09:30:00+00:00,2025-01-04 08:00:00+00:00,TSHA,LONG,432,1.850000023841858,1.8685000240802765,1.8685000240802765,1.8407500237226486,True,False,7.992000102996826,0.9985985343683353,10012.012419645489,corporate_action,-0.10069388191416243,2.162160072298822,https://www.globenewswire.com/news-release/2025/01/03/3003988/0/en/Taysha-Gene-Therapies-Announces-Inducement-Grant-Under-Nasdaq-Listing-Rule-5635-c-4.html
2025-01-06 01:00:00+00:00,pre_market,2025-01-06 09:30:00+00:00,2025-01-07 01:00:00+00:00,SANN.SW,LONG,55,14.460000038146973,14.604600038528442,14.604600038528442,14.387700037956238,True,False,7.953000020980827,0.9929322507350664,10019.96541966647,licensing_agreements,0.26867471153291783,3.7344395603627367,https://www.globenewswire.com/news-release/2025/01/06/3004317/0/en/Santhera-Enters-into-Supply-and-Distribution-Agreement-for-AGAMREE-Vamorolone-with-Clinigen-Group.html
2025-01-06 01:00:00+00:00,pre_market,2025-01-06 09:30:00+00:00,2025-01-07 01:00:00+00:00,SANN.SW,LONG,55,14.460000038146973,14.604600038528442,14.604600038528442,14.387700037956238,True,False,7.953000020980827,0.9921441451997489,10027.918419687452,business_contracts,1.2226308502755163,3.7344395603627367,https://www.globenewswire.com/news-release/2025/01/06/3004317/0/de/Santhera-geht-Liefer-und-Vertriebsvereinbarung-f%C3%BCr-AGAMREE-Vamorolon-mit-der-Clinigen-Group-ein.html
2025-01-06 03:47:00+00:00,pre_market,2025-01-06 09:30:00+00:00,2025-01-07 03:47:00+00:00,OCS,LONG,45,17.559999465942383,17.735599460601808,17.735599460601808,17.472199468612672,True,False,7.90199975967413,0.9850000056044056,10035.820419447125,clinical_study,0.49620093421661293,3.0751761500601154,https://www.globenewswire.com/news-release/2025/01/06/3004348/0/is/Oculis-tilkynnir-um-j%C3%A1kv%C3%A6%C3%B0ar-ni%C3%B0urst%C3%B6%C3%B0ur-%C3%BAr-fasa-2-ACUITY-ranns%C3%B3knar-%C3%A1-OCS-05-vi%C3%B0-sj%C3%B3ntaugab%C3%B3lgu-a%C3%B0alvi%C3%B0mi%C3%B0i-um-%C3%B6ryggi-n%C3%A1%C3%B0-auk-lykilvi%C3%B0mi%C3%B0a-um-virkni-sem-opnar-%C3%A1-%C3%BEr%C3%B3un-sem-m%C3%B6gulegt.html
2025-01-06 03:47:00+00:00,pre_market,2025-01-06 09:30:00+00:00,2025-01-07 03:47:00+00:00,OCS,LONG,45,17.559999465942383,17.735599460601808,17.735599460601808,17.472199468612672,True,False,7.90199975967413,0.9842244367438387,10043.722419206799,clinical_study,0.4851028219117042,3.0751761500601154,https://www.globenewswire.com/news-release/2025/01/06/3004348/0/en/Oculis-Announces-Positive-OCS-05-Phase-2-ACUITY-Trial-in-Acute-Optic-Neuritis-Met-Primary-Safety-Endpoint-and-Key-Secondary-Efficacy-Endpoints-Opening-Development-Pathways-as-a-Pot.html
2025-01-06 03:53:00+00:00,pre_market,2025-01-06 09:30:00+00:00,2025-01-07 03:53:00+00:00,OCS,LONG,45,17.559999465942383,17.735599460601808,17.735599460601808,17.472199468612672,True,False,7.90199975967413,0.9834500882564949,10051.624418966472,clinical_study,-0.11005930906081747,3.0751761500601154,https://www.globenewswire.com/news-release/2025/01/06/3004350/0/en/Oculis-Announces-Positive-OCS-05-Phase-2-ACUITY-Trial-in-Acute-Optic-Neuritis-Met-Primary-Safety-Endpoint-and-Key-Secondary-Efficacy-Endpoints-Opening-Development-Pathways-as-a-Pot.html
2025-01-06 07:00:00+00:00,pre_market,2025-01-06 09:30:00+00:00,2025-01-07 07:00:00+00:00,SEPN,LONG,33,23.690000534057617,23.571550531387327,23.926900539398194,23.571550531387327,False,True,-3.908850088119568,-0.486096814454181,10047.715568878353,management_changes,-0.6770946000465279,-3.4191699241480715,https://www.globenewswire.com/news-release/2025/01/06/3004454/0/en/Septerna-Expands-Leadership-with-Appointment-of-Industry-Veteran-Gil-Labrucherie-as-Chief-Financial-Officer.html
2025-01-06 08:00:00+00:00,pre_market,2025-01-06 09:30:00+00:00,2025-01-07 08:00:00+00:00,FBIO,SHORT,360,2.2300000190734863,2.2411500191688534,2.2077000188827514,2.2411500191688534,False,True,-4.014000034332135,-0.49936724507372593,10043.70156884402,regulatory_filings,-0.35264064501437076,3.1390104324699157,https://www.globenewswire.com/news-release/2025/01/06/3004566/28889/en/Fortress-Biotech-and-Cyprium-Therapeutics-Announce-U-S-FDA-Acceptance-and-Priority-Review-of-NDA-for-CUTX-101-for-Treatment-of-Menkes-Disease.html
2025-01-06 08:00:00+00:00,pre_market,2025-01-06 09:30:00+00:00,2025-01-07 08:00:00+00:00,RAPT,LONG,481,1.6699999570846558,1.6699999570846558,1.6866999566555023,1.6616499572992325,False,False,0.0,0.0,10043.70156884402,management_changes,0.4370742627498281,0.0,https://www.globenewswire.com/news-release/2025/01/06/3004538/0/en/RAPT-Therapeutics-Names-Lori-Lyons-Williams-Chair-of-the-Company-s-Board-of-Directors.html
2025-01-06 08:00:00+00:00,pre_market,2025-01-06 09:30:00+00:00,2025-01-07 08:00:00+00:00,IMMP,LONG,368,2.180000066757202,2.201800067424774,2.201800067424774,2.169100066423416,True,False,8.02240024566651,0.9984367056654104,10051.723969089688,clinical_study,1.354885717968482,3.2110060137256915,https://www.globenewswire.com/news-release/2025/01/06/3004565/0/en/Patient-Enrolment-Completed-for-INSIGHT-003.html
2025-01-06 08:00:00+00:00,pre_market,2025-01-06 09:30:00+00:00,2025-01-07 08:00:00+00:00,SPRY,SHORT,71,11.1899995803833,11.245949578285217,11.078099584579467,11.245949578285217,False,True,-3.9724498510360213,-0.4940010618143469,10047.75151923865,regulatory_filings,5.0096359740337935,0.9830260453664338,https://www.globenewswire.com/news-release/2025/01/06/3004537/0/en/ARS-Pharmaceuticals-Files-for-Approval-of-neffy-in-Canada-and-the-United-Kingdom-on-Behalf-of-Licensing-Partner-ALK-Abell%C3%B3-A-S.html
2025-01-07 07:00:00+00:00,pre_market,2025-01-07 09:30:00+00:00,2025-01-08 07:00:00+00:00,MBX,SHORT,49,16.280000686645508,16.117200679779053,16.117200679779053,16.361400690078735,True,False,7.977200336456285,0.992411128149189,10055.728719575107,clinical_study,29.549339727294203,-3.255532335943128,https://www.globenewswire.com/news-release/2025/01/07/3005223/0/en/MBX-Biosciences-Announces-Positive-Phase-1-Topline-Results-for-MBX-1416-for-the-Treatment-of-Post-bariatric-Hypoglycemia.html
2025-01-07 07:00:00+00:00,pre_market,2025-01-07 09:30:00+00:00,2025-01-08 07:00:00+00:00,IMRX,LONG,340,2.359999895095825,2.3835998940467835,2.3835998940467835,2.348199895620346,True,False,8.02399964332583,0.9974413425286887,10063.752719218433,clinical_study,2.177237724143382,58.47458371962701,https://www.globenewswire.com/news-release/2025/01/07/3005238/0/en/Immuneering-Announces-Positive-Data-Update-from-Three-Pancreatic-Cancer-Arms-of-Ongoing-Phase-2a-Trial-of-IMM-1-104-Plans-to-Expand-Trial-with-Additional-Arms.html
2025-01-07 07:05:00+00:00,pre_market,2025-01-07 09:30:00+00:00,2025-01-08 07:05:00+00:00,KBLB,LONG,8051,0.10000000149011612,0.10000000149011612,0.10100000150501728,0.09950000148266554,False,False,0.0,0.0,10063.752719218433,product_services_announcement,0.8570288313204366,0.0,https://www.globenewswire.com/news-release/2025/01/07/3005249/0/en/Kraig-Biocraft-Laboratories-Announces-Breakthrough-Transgenic-Development-Inspired-by-Darwin-s-Bark-Spider.html
2025-01-07 08:00:00+00:00,pre_market,2025-01-07 09:30:00+00:00,2025-01-08 08:00:00+00:00,PCRX,SHORT,43,18.6299991607666,18.723149156570432,18.443699169158936,18.723149156570432,False,True,-4.005449819564728,-0.4975094692951425,10059.74726939887,product_services_announcement,4.785626221751472,0.9125071602362327,https://www.globenewswire.com/news-release/2025/01/07/3005343/0/en/Pacira-BioSciences-Receives-FDA-510k-Clearance-for-New-iovera-SmartTip-to-Manage-Chronic-Low-Back-Pain-via-Long-lasting-Medial-Branch-Nerve-Block.html
2025-01-07 08:00:00+00:00,pre_market,2025-01-07 09:30:00+00:00,2025-01-08 08:00:00+00:00,CRSP,LONG,18,42.43000030517578,42.854300308227536,42.854300308227536,42.217850303649904,True,False,7.6374000549315895,0.9490049613577382,10067.3846694538,management_changes,0.43464440213966254,1.1548382282471004,https://www.globenewswire.com/news-release/2025/01/07/3005342/0/en/CRISPR-Therapeutics-Proposes-New-Appointment-to-the-Board-of-Directors.html
2025-01-07 08:00:00+00:00,pre_market,2025-01-07 09:30:00+00:00,2025-01-08 08:00:00+00:00,ECOR,LONG,44,17.989999771118164,17.900049772262573,18.169899768829346,17.900049772262573,False,True,-3.9577999496460023,-0.491413619275751,10063.426869504154,patents,-0.19264076807774155,-1.0561452833515392,https://www.globenewswire.com/news-release/2025/01/07/3005370/0/en/electroCore-Expands-Intellectual-Property-Portfolio.html
2025-01-07 08:00:00+00:00,pre_market,2025-01-07 09:30:00+00:00,2025-01-08 08:00:00+00:00,RZLT,LONG,154,5.210000038146973,5.262100038528442,5.262100038528442,5.1839500379562375,True,False,8.023400058746278,0.9966038610391381,10071.4502695629,clinical_study,3.9637318060808764,1.1516303712136065,https://www.globenewswire.com/news-release/2025/01/07/3005336/0/en/Rezolute-Receives-Breakthrough-Therapy-Designation-from-FDA-for-Ersodetug-in-the-Treatment-of-Hypoglycemia-Due-to-Congenital-Hyperinsulinism.html
2025-01-07 09:15:00+00:00,pre_market,2025-01-07 09:30:00+00:00,2025-01-08 09:15:00+00:00,RENB,LONG,805,1.0,1.01,1.01,0.995,True,False,8.050000000000008,0.9991113226672091,10079.5002695629,management_changes,-2.1293925886208345,4.999995231628418,https://www.globenewswire.com/news-release/2025/01/07/3005537/0/en/Renovaro-Appoints-Nathen-Fuentes-as-Chief-Financial-Officer.html
2025-01-07 09:34:00+00:00,regular_market,2025-01-07 09:39:00+00:00,2025-01-07 14:34:00+00:00,IMMX,LONG,349,2.309999942779541,2.3330999422073364,2.3330999422073364,2.298449943065643,True,False,8.061899800300592,0.9997891245468213,10087.5621693632,clinical_study,0.6357368593385001,-1.2987000923330156,https://www.globenewswire.com/news-release/2025/01/07/3005561/0/en/Immix-Biopharma-Accelerates-Enrollment-in-U-S-AL-Amyloidosis-Trial-of-NXC-201-CAR-T.html
2025-01-08 07:00:00+00:00,pre_market,2025-01-08 09:30:00+00:00,2025-01-09 07:00:00+00:00,JSPR,SHORT,45,17.709999084472656,17.53289909362793,17.53289909362793,17.798549079895018,True,False,7.969499588012727,0.9875403311288613,10095.531668951213,clinical_study,2.123670370263025,-50.64934939053154,https://www.globenewswire.com/news-release/2025/01/08/3006120/0/en/Jasper-Therapeutics-Reports-Positive-Data-from-BEACON-Study-of-Briquilimab-in-Chronic-Spontaneous-Urticaria.html
2025-01-08 07:00:00+00:00,pre_market,2025-01-08 09:30:00+00:00,2025-01-09 07:00:00+00:00,MLTX,SHORT,16,50.209999084472656,50.46104907989501,49.70789909362793,50.46104907989501,False,True,-4.016799926757699,-0.4973487353706391,10091.514869024455,clinical_study,17.205870564277234,0.5775760223366065,https://www.globenewswire.com/news-release/2025/01/08/3006081/0/en/MoonLake-initiates-three-new-clinical-trials-and-further-expands-the-portfolio-of-indications-for-the-Nanobody-sonelokimab.html
2025-01-08 07:30:00+00:00,pre_market,2025-01-08 09:30:00+00:00,2025-01-09 07:30:00+00:00,RVVTF,SHORT,134553,0.006000000052154064,0.005940000051632524,0.005940000051632524,0.0060300000524148335,True,False,8.07318007017483,0.9999960579450724,10099.58804909463,clinical_study,9.902394849049076,-16.666669253673795,https://www.globenewswire.com/news-release/2025/01/08/3006148/0/en/Revive-Therapeutics-Provides-Update-on-Research-Study-Evaluating-Bucillamine-for-Nerve-Agent-Exposure.html
2025-01-08 08:00:00+00:00,pre_market,2025-01-08 09:30:00+00:00,2025-01-09 08:00:00+00:00,CRBP,LONG,64,12.600000381469727,12.65999984741211,12.726000385284424,12.537000379562377,False,False,3.8399658203125,0.4752626792358045,10103.428014914942,clinical_study,4.420905451079867,0.4761862232212423,https://www.globenewswire.com/news-release/2025/01/08/3006205/0/en/Corbus-Pharmaceuticals-Announces-that-Clinical-Data-for-CRB-701-from-Western-Dose-Escalation-Study-to-be-Presented-at-ASCO-GU-2025.html
2025-01-08 08:00:00+00:00,pre_market,2025-01-08 09:30:00+00:00,2025-01-09 08:00:00+00:00,MLYS,SHORT,62,12.979999542236328,12.850199546813965,12.850199546813965,13.044899539947508,True,False,8.047599716186532,0.9956521321657432,10111.475614631128,clinical_study,0.8955944720438689,-1.3097005286206636,https://www.globenewswire.com/news-release/2025/01/08/3006229/0/en/Mineralys-Therapeutics-Announces-Phase-2-Clinical-Trial-of-Lorundrostat-for-Obstructive-Sleep-Apnea-in-Patients-with-Hypertension.html
2025-01-13 06:30:00+00:00,pre_market,2025-01-13 09:30:00+00:00,2025-01-14 06:30:00+00:00,OCGN,LONG,1027,0.7870000004768372,0.7948700004816055,0.7948700004816055,0.7830650004744529,True,False,8.082490004897085,0.9991729091946115,10119.558104636026,clinical_study,0.6372609989654244,1.6518438927846495,https://www.globenewswire.com/news-release/2025/01/13/3008252/0/en/Ocugen-Inc-Announces-Positive-2-Year-Data-Across-Multiple-Mutations-from-Phase-1-2-Clinical-Trial-of-OCU400-A-Novel-Modifier-Gene-Therapy-for-Retinitis-Pigmentosa.html
2025-01-13 07:00:00+00:00,pre_market,2025-01-13 09:30:00+00:00,2025-01-14 07:00:00+00:00,AKRO,LONG,32,24.84000015258789,24.71580015182495,25.08840015411377,24.71580015182495,False,True,-3.9744000244140807,-0.49093053067619963,10115.583704611612,clinical_study,7.045167263412184,-1.2077263897653086,https://www.globenewswire.com/news-release/2025/01/13/3008318/0/en/Akero-Therapeutics-Completes-Enrollment-of-the-Double-Blind-Portion-of-the-Phase-3-SYNCHRONY-Real-World-Study-Evaluating-Efruxifermin-EFX-in-Patients-with-Non-Invasively-Diagnosed-.html
2025-01-13 07:35:00+00:00,pre_market,2025-01-13 09:30:00+00:00,2025-01-14 07:35:00+00:00,XFOR,LONG,1419,0.5699999928474426,0.5756999927759171,0.5756999927759171,0.5671499928832054,True,False,8.08829989850528,0.9994850686196549,10123.672004510117,licensing_agreements,0.7785390832758323,5.087716601451865,https://www.globenewswire.com/news-release/2025/01/13/3008383/0/en/X4-Pharmaceuticals-and-Norgine-Enter-into-Exclusive-Licensing-Agreement-to-Commercialize-Mavorixafor-in-Europe-Australia-and-New-Zealand.html
2025-01-13 08:00:00+00:00,pre_market,2025-01-13 09:30:00+00:00,2025-01-14 08:00:00+00:00,HUMA,LONG,175,4.610000133514404,4.586950132846832,4.656100134849549,4.586950132846832,False,True,-4.033750116825141,-0.4980591670477985,10119.638254393292,product_services_announcement,0.3010793416602863,-0.6507637513988344,https://www.globenewswire.com/news-release/2025/01/13/3008453/0/en/Humacyte-Provides-Update-on-Commercial-Launch-and-Pricing-of-Symvess-acellular-tissue-engineered-vessel-tyod-for-Extremity-Vascular-Trauma.html
2025-01-13 08:00:00+00:00,pre_market,2025-01-13 09:30:00+00:00,2025-01-14 08:00:00+00:00,ORIC,LONG,101,7.960000038146973,8.039600038528443,8.039600038528443,7.920200037956238,True,False,8.039600038528478,0.9930690994609175,10127.67785443182,clinical_study,0.49603354295006663,9.422110507609926,https://www.globenewswire.com/news-release/2025/01/13/3008455/0/en/ORIC-Pharmaceuticals-Announces-Clinical-Supply-Agreement-to-Evaluate-ORIC-114-in-Combination-with-Amivantamab-for-the-First-Line-Treatment-of-NSCLC-with-EGFR-Exon-20-Insertion-Muta.html
2025-01-13 08:00:00+00:00,pre_market,2025-01-13 09:30:00+00:00,2025-01-14 08:00:00+00:00,WINT,LONG,3116,0.25999999046325684,0.25869999051094056,0.2625999903678894,0.25869999051094056,False,True,-4.050799851417521,-0.49996651621932653,10123.627054580404,management_changes,0.6068702219997695,-3.8461503192516595,https://www.globenewswire.com/news-release/2025/01/13/3008408/0/en/Windtree-Announces-the-Addition-of-Leanne-Kelly-to-Its-Board-of-Directors.html
2025-01-13 08:00:00+00:00,pre_market,2025-01-13 09:30:00+00:00,2025-01-14 08:00:00+00:00,ANNX,LONG,167,4.829999923706055,4.809999942779541,4.878299922943115,4.805849924087524,False,False,-3.339996814727783,-0.4124012071859922,10120.287057765676,clinical_study,0.6133924731644563,-0.4140782865927606,https://www.globenewswire.com/news-release/2025/01/13/3008474/0/en/Annexon-Provides-2025-Outlook-with-Strong-Momentum-Accelerating-into-Breakthrough-Year.html
2025-01-13 08:00:00+00:00,pre_market,2025-01-13 09:30:00+00:00,2025-01-14 08:00:00+00:00,CADL,LONG,98,8.180000305175781,8.139100303649903,8.261800308227539,8.139100303649903,False,True,-4.008200149536112,-0.49506996771159634,10116.27885761614,clinical_study,2.222801338099164,-0.733501434941693,https://www.globenewswire.com/news-release/2025/01/13/3008449/0/en/Candel-Therapeutics-Provides-Corporate-Update-and-Highlights-Strong-Pipeline-Momentum-and-Key-Value-Drivers-for-2025.html
2025-01-13 08:00:00+00:00,pre_market,2025-01-13 09:30:00+00:00,2025-01-14 08:00:00+00:00,IMRX,LONG,390,2.069999933242798,2.059649933576584,2.090699932575226,2.059649933576584,False,True,-4.036499869823449,-0.49876292540914513,10112.242357746316,clinical_study,4.2559249479269115,-1.449274026921029,https://www.globenewswire.com/news-release/2025/01/13/3008480/0/en/Immuneering-Provides-Positive-Update-on-Phase-2a-Arm-Studying-IMM-1-104-in-Combination-with-Modified-FOLFIRINOX-for-First-Line-Pancreatic-Cancer.html
2025-01-13 08:05:00+00:00,pre_market,2025-01-13 09:30:00+00:00,2025-01-14 08:05:00+00:00,ORIC,LONG,101,7.960000038146973,8.039600038528443,8.039600038528443,7.920200037956238,True,False,8.039600038528478,0.9937954108133439,10120.281957784844,clinical_study,3.462956067630822,9.422110507609926,https://www.globenewswire.com/news-release/2025/01/13/3008495/0/en/ORIC-Pharmaceuticals-Provides-Early-Phase-1b-Combination-Data-for-ORIC-944-Operational-Highlights-for-2024-and-Anticipated-Upcoming-Milestones.html
2025-01-13 09:00:00+00:00,pre_market,2025-01-13 09:30:00+00:00,2025-01-14 09:00:00+00:00,SCLX,SHORT,1779,0.45500001311302185,0.453000009059906,0.45045001298189163,0.45727501317858693,False,False,3.5580072104930878,0.43946493108279394,10123.839964995337,product_services_announcement,-0.7028336730998238,-0.439561317687049,https://www.globenewswire.com/news-release/2025/01/13/3008591/0/en/Scilex-Holding-Company-Announces-Pain-Medicine-News-Published-Retrospective-Claims-Data-on-ZTlido-vs-Lidocaine-5-Patch.html
2025-01-14 01:00:00+00:00,pre_market,2025-01-14 09:30:00+00:00,2025-01-15 01:00:00+00:00,SANN.SW,SHORT,65,12.319999694824219,12.38159969329834,12.196799697875976,12.38159969329834,False,True,-4.0039999008178295,-0.49437761692478427,10119.835965094519,regulatory_filings,-0.5468392757535185,4.0584416589722485,https://www.globenewswire.com/news-release/2025/01/14/3009000/0/de/Santhera-erh%C3%A4lt-positive-Empfehlung-vom-Scottish-Medicines-Consortium-f%C3%BCr-den-Einsatz-von-AGAMREE-Vamorolon-bei-Patienten-mit-Duchenne-Muskeldystrophie-in-Schottland.html
2025-01-14 01:00:00+00:00,pre_market,2025-01-14 09:30:00+00:00,2025-01-15 01:00:00+00:00,SANN.SW,SHORT,65,12.319999694824219,12.38159969329834,12.196799697875976,12.38159969329834,False,True,-4.0039999008178295,-0.4945732216693633,10115.8319651937,regulatory_filings,-0.5468392757535185,4.0584416589722485,https://www.globenewswire.com/news-release/2025/01/14/3009000/0/en/Santhera-Receives-Positive-Recommendation-from-Scottish-Medicines-Consortium-for-the-Use-of-AGAMREE-Vamorolone-in-Duchenne-Muscular-Dystrophy-Patients-in-NHS-Scotland.html
2025-01-14 07:00:00+00:00,pre_market,2025-01-14 09:30:00+00:00,2025-01-15 07:00:00+00:00,CCCC,SHORT,231,3.5,3.5174999999999996,3.465,3.5174999999999996,False,True,-4.042499999999913,-0.4995263876848248,10111.7894651937,clinical_study,2.432548656199076,1.7142840794154575,https://www.globenewswire.com/news-release/2025/01/14/3009167/0/en/C4-Therapeutics-Announces-2025-Milestones-Across-Clinical-Portfolio-of-Degrader-Medicines-Pursuing-Targets-of-High-Unmet-Need-in-Oncology.html
2025-01-14 08:00:00+00:00,pre_market,2025-01-14 09:30:00+00:00,2025-01-15 08:00:00+00:00,ADAG,LONG,454,1.7799999713897705,1.7977999711036683,1.7977999711036683,1.7710999715328217,True,False,8.081199870109595,0.9989824127972476,10119.87066506381,clinical_study,4.8495574834224575,5.617978957818797,https://www.globenewswire.com/news-release/2025/01/14/3009241/0/en/Adagene-to-Host-Virtual-KOL-Event-to-Discuss-Anti-CTLA-4-SAFEbody-ADG126-in-Advanced-Metastatic-Microsatellite-Stable-MSS-Colorectal-Cancer-CRC-on-January-25-2025.html
2025-01-14 08:00:00+00:00,pre_market,2025-01-14 09:30:00+00:00,2025-01-15 08:00:00+00:00,VXRT,LONG,1124,0.7200000286102295,0.7272000288963318,0.7272000288963318,0.7164000284671783,True,False,8.09280032157904,0.999617558048111,10127.96346538539,clinical_study,0.32828872805885156,15.277770879092314,https://www.globenewswire.com/news-release/2025/01/14/3009248/25416/en/Vaxart-Highlights-Progress-of-COVID-19-Norovirus-and-Influenza-Programs.html
2025-01-16 01:00:00+00:00,pre_market,2025-01-16 09:30:00+00:00,2025-01-17 01:00:00+00:00,SANN.SW,SHORT,57,14.0,14.069999999999999,13.86,14.069999999999999,False,True,-3.989999999999915,-0.49244845886794564,10123.97346538539,regulatory_filings,-0.6930937879623983,2.857140132359096,https://www.globenewswire.com/news-release/2025/01/16/3010530/0/en/Santhera-Receives-Positive-NICE-Final-Guidance-for-AGAMREE-Vamorolone-as-a-Treatment-for-Duchenne-Muscular-Dystrophy.html
2025-01-16 01:00:00+00:00,pre_market,2025-01-16 09:30:00+00:00,2025-01-17 01:00:00+00:00,SANN.SW,LONG,57,14.0,14.14,14.14,13.93,True,False,7.980000000000032,0.9852850794310454,10131.95346538539,major_shareholder_announcements,1.1277180986600412,2.857140132359096,https://www.globenewswire.com/news-release/2025/01/16/3010531/0/en/Santhera-Pharmaceuticals-Provides-Update-on-Royalty-Agreement-for-AGAMREE-Vamorolone-and-Warrants-held-by-Idorsia.html
2025-01-16 01:00:00+00:00,pre_market,2025-01-16 09:30:00+00:00,2025-01-17 01:00:00+00:00,SANN.SW,LONG,57,14.0,14.14,14.14,13.93,True,False,7.980000000000032,0.9845090617597521,10139.93346538539,licensing_agreements,1.0787555347446838,2.857140132359096,https://www.globenewswire.com/news-release/2025/01/16/3010531/0/de/Santhera-Pharmaceuticals-gibt-ein-Update-zur-Lizenzvereinbarung-f%C3%BCr-AGAMREE-Vamorolon-und-den-von-Idorsia-gehaltenen-Warrants.html
2025-01-16 01:00:00+00:00,pre_market,2025-01-16 09:30:00+00:00,2025-01-17 01:00:00+00:00,SANN.SW,LONG,57,14.0,14.14,14.14,13.93,True,False,7.980000000000032,0.9837342655207372,10147.913465385389,product_services_announcement,-1.0030554200925943,2.857140132359096,https://www.globenewswire.com/news-release/2025/01/16/3010530/0/de/Santhera-erh%C3%A4lt-positive-endg%C3%BCltige-NICE-Empfehlung-f%C3%BCr-AGAMREE-Vamorolon-zur-Behandlung-von-Duchenne-Muskeldystrophie.html
2025-01-16 07:30:00+00:00,pre_market,2025-01-16 09:30:00+00:00,2025-01-17 07:30:00+00:00,OCGN,LONG,1113,0.7289999723434448,0.7362899720668793,0.7362899720668793,0.7253549724817276,True,False,8.113769692182565,0.9994381751306187,10156.027235077572,clinical_study,1.5746368184159352,1.371749032548716,https://www.globenewswire.com/news-release/2025/01/16/3010712/0/en/Ocugen-Inc-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-OCU200-a-Novel-Integrin-Targeting-Biologic-for-Diabetic-Macular-Edema.html
2025-01-16 08:19:00+00:00,pre_market,2025-01-16 09:30:00+00:00,2025-01-17 08:19:00+00:00,BMRA,LONG,2321,0.3499999940395355,0.35349999397993087,0.35349999397993087,0.3482499940693378,True,False,8.123499861657605,0.999837297796932,10164.15073493923,product_services_announcement,6.508745777511718,214.2857264499277,https://www.globenewswire.com/news-release/2025/01/16/3010764/0/en/United-Arab-Emirates-Ministry-of-Health-and-Prevention-Approves-Biomerica-s-Fortel-PSA-Screening-Test-to-Detect-an-Early-Sign-of-Prostate-Cancer.html
2025-01-16 15:38:00+00:00,regular_market,2025-01-16 15:43:00+00:00,2025-01-16 15:52:00+00:00,SCLX,LONG,1797,0.4523000121116638,0.4500385120511055,0.45682301223278043,0.4500385120511055,False,True,-4.0639156088232795,-0.49978543643267515,10160.086819330407,licensing_agreements,0.35487373337373684,3.6922394701868066,https://www.globenewswire.com/news-release/2025/01/16/3011130/0/en/Scilex-Holding-Company-Amends-its-License-Agreement-with-Romeg-Therapeutics-LLC-For-the-Worldwide-Rights-to-Commercialize-Gloperba-an-FDA-Approved-Prophylactic-Treatment-for-Painfu.html
2025-01-21 02:30:00+00:00,pre_market,2025-01-21 09:30:00+00:00,2025-01-22 02:30:00+00:00,NANO.PA,LONG,267,3.0339999198913574,3.064339919090271,3.064339919090271,3.0188299202919007,True,False,8.100779786109905,0.9966425398424624,10168.187599116516,clinical_study,-0.22296333826367964,1.186552877454576,https://www.globenewswire.com/news-release/2025/01/21/3012345/0/fr/NANOBIOTIX-annonce-le-traitement-du-premier-patient-dans-une-nouvelle-%C3%A9tude-randomis%C3%A9e-de-phase-2-%C3%A9valuant-JNJ-1900-NBTXR3-chez-des-patients-atteints-d-un-cancer-du-poumon-non-%C3%A0-pe.html
2025-01-21 02:30:00+00:00,pre_market,2025-01-21 09:30:00+00:00,2025-01-22 02:30:00+00:00,NANO.PA,LONG,268,3.0339999198913574,3.064339919090271,3.064339919090271,3.0188299202919007,True,False,8.131119785308819,0.9995783056283437,10176.318718901824,clinical_study,0.033582239480609496,1.186552877454576,https://www.globenewswire.com/news-release/2025/01/21/3012345/0/en/NANOBIOTIX-Announces-First-Patient-Dosed-in-a-New-Randomized-Phase-2-Study-Evaluating-JNJ-1900-NBTXR3-for-Patients-With-Stage-3-Unresectable-Non-Small-Cell-Lung-Cancer.html
2025-01-21 06:00:00+00:00,pre_market,2025-01-21 09:30:00+00:00,2025-01-22 06:00:00+00:00,SCLX,LONG,1813,0.4490000009536743,0.45100000500679016,0.45349000096321107,0.44675500094890597,False,False,3.6260073482990265,0.4453977229462117,10179.944726250123,regulatory_filings,0.833820343607769,0.44543520019328364,https://www.globenewswire.com/news-release/2025/01/21/3012452/0/en/Scilex-Holding-Company-Announces-Filing-of-its-Quarterly-Report-on-Form-10-Q-for-the-Quarter-Ended-September-30-2024.html
2025-01-21 07:00:00+00:00,pre_market,2025-01-21 09:30:00+00:00,2025-01-22 07:00:00+00:00,SCLX,LONG,1813,0.4490000009536743,0.45100000500679016,0.45349000096321107,0.44675500094890597,False,False,3.6260073482990265,0.44523907616965763,10183.570733598423,regulatory_filings,0.32956653016766074,0.44543520019328364,https://www.globenewswire.com/news-release/2025/01/21/3012506/0/en/Scilex-Holding-Company-Announces-that-It-Will-Be-Filing-Today-of-a-Supplemental-New-Drug-Application-with-the-FDA-for-ELYXYB-in-Acute-Pain-Indication.html
2025-01-21 07:00:00+00:00,pre_market,2025-01-21 09:30:00+00:00,2025-01-22 07:00:00+00:00,NSPR,SHORT,299,2.7200000286102295,2.7336000287532802,2.692800028324127,2.7336000287532802,False,True,-4.066400042772171,-0.49913730521800065,10179.504333555651,shares_issue,-6.503673833452624,3.676467043408923,https://www.globenewswire.com/news-release/2025/01/21/3012510/0/en/InspireMD-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html
2025-01-21 08:00:00+00:00,pre_market,2025-01-21 09:30:00+00:00,2025-01-22 08:00:00+00:00,PCRX,LONG,36,22.360000610351562,22.248200607299804,22.58360061645508,22.248200607299804,False,True,-4.024800109863307,-0.49422839978023075,10175.479533445789,management_changes,0.34300065254234446,-0.5814001098687376,https://www.globenewswire.com/news-release/2025/01/21/3012610/0/en/Pacira-BioSciences-Strengthens-Executive-Leadership-Team-with-Two-Key-Appointments.html
2025-01-21 08:00:00+00:00,pre_market,2025-01-21 09:30:00+00:00,2025-01-22 08:00:00+00:00,HUMA,LONG,184,4.409999847412109,4.449999809265137,4.454099845886231,4.387949848175049,False,False,7.359992980957031,0.9041334313490419,10182.839526426746,clinical_study,6.796649884935556,0.9070286448309121,https://www.globenewswire.com/news-release/2025/01/21/3012571/0/en/Humacyte-Announces-Planned-IND-Filing-in-2025-to-Support-First-In-Human-Clinical-Study-of-Small-Diameter-ATEV-for-Coronary-Artery-Bypass-Grafting.html
2025-01-21 08:00:00+00:00,pre_market,2025-01-21 09:30:00+00:00,2025-01-22 08:00:00+00:00,SPRY,LONG,64,12.569999694824219,12.695699691772461,12.695699691772461,12.507149696350098,True,False,8.0447998046875,0.9875437720256521,10190.884326231433,product_services_announcement,0.5767442976003934,1.3524270518792771,https://www.globenewswire.com/news-release/2025/01/21/3012602/0/en/ARS-Pharmaceuticals-Launches-neffyinSchools-Program-Providing-Free-Life-Saving-Needle-Free-Epinephrine-For-Emergency-Use-to-Eligible-K-12-Schools.html
2025-01-21 08:01:00+00:00,pre_market,2025-01-21 09:30:00+00:00,2025-01-22 08:01:00+00:00,MYNZ,LONG,168,4.829999923706055,4.878299922943115,4.878299922943115,4.805849924087524,True,False,8.11439987182613,0.9953012432566313,10198.998726103258,clinical_study,19.92880772438775,4.968949311518214,https://www.globenewswire.com/news-release/2025/01/21/3012627/0/en/Mainz-Biomed-Initiates-U-S-Clinical-Study-to-Evaluate-Performance-of-Next-Generation-Test-on-Advanced-Adenomas-over-Large-Patient-Population.html
2025-01-21 09:00:00+00:00,pre_market,2025-01-21 09:30:00+00:00,2025-01-22 09:00:00+00:00,SCLX,LONG,1817,0.4490000009536743,0.45100000500679016,0.45349000096321107,0.44675500094890597,False,False,3.63400736451149,0.44538776086061177,10202.63273346777,licensing_agreements,0.5167721066121969,0.44543520019328364,https://www.globenewswire.com/news-release/2025/01/21/3012764/0/en/Scilex-Holding-Company-Announces-that-Its-Note-Holders-Intend-to-Participate-in-the-Funding-and-Licensing-of-Gloperba-Ex-U-S-Commercialization-Rights-from-Romeg-Therapeutics-LLC.html
2025-01-21 09:46:00+00:00,regular_market,2025-01-21 09:51:00+00:00,2025-01-21 14:31:00+00:00,SCLX,SHORT,1809,0.45100000500679016,0.4532550050318241,0.44649000495672225,0.4532550050318241,False,True,-4.079295045286373,-0.49978460852376755,10198.553438422483,financing_agreements,-1.3753193647911015,-6.2084250173246645,https://www.globenewswire.com/news-release/2025/01/21/3012815/0/en/Scilex-Holding-Company-Announces-Extension-of-the-Maturity-Date-of-its-Secured-Promissory-Note-Issued-to-Oramed-Pharmaceuticals-Inc-to-December-31-2025.html
2025-01-21 11:49:00+00:00,regular_market,2025-01-21 11:54:00+00:00,2025-01-21 14:31:00+00:00,SCLX,LONG,1809,0.45100000500679016,0.45551000505685807,0.45551000505685807,0.44874500498175623,True,False,8.158590090572845,0.9999690323526436,10206.712028513055,regulatory_filings,0.8281287876602501,-6.2084250173246645,https://www.globenewswire.com/news-release/2025/01/21/3012920/0/en/Scilex-Holding-Company-Announces-that-It-Regains-Nasdaq-Compliance-Under-Listing-Rule-5250-c-1.html
2025-01-22 07:00:00+00:00,pre_market,2025-01-22 09:30:00+00:00,2025-01-23 07:00:00+00:00,CHRS,LONG,618,1.3200000524520874,1.3332000529766084,1.3332000529766084,1.313400052189827,True,False,8.157600324153961,0.999048506189508,10214.869628837208,clinical_study,2.7510805626281027,2.2727250149756664,https://www.globenewswire.com/news-release/2025/01/22/3013336/33333/en/Coherus-Presents-Final-Phase-2-Clinical-Casdozokitug-Combination-Data-in-Patients-with-Metastatic-Hepatocellular-Carcinoma-at-ASCO-GI-2025.html
2025-01-22 07:30:00+00:00,pre_market,2025-01-22 09:30:00+00:00,2025-01-23 07:30:00+00:00,NTLA,SHORT,82,9.9399995803833,9.880000114440918,9.840599584579468,9.989699578285217,False,False,4.919956207275391,0.6020581253168971,10219.789585044484,clinical_study,0.8868013020850922,-0.6036163830508849,https://www.globenewswire.com/news-release/2025/01/22/3013374/0/en/Intellia-Therapeutics-Announces-First-Patient-Dosed-in-the-HAELO-Phase-3-Study-of-NTLA-2002-an-Investigational-In-Vivo-CRISPR-Gene-Editing-Treatment-for-Hereditary-Angioedema.html
2025-01-22 07:30:00+00:00,pre_market,2025-01-22 09:30:00+00:00,2025-01-23 07:30:00+00:00,ELTX,LONG,126,6.449999809265137,6.460000038146973,6.514499807357788,6.417749810218811,False,False,1.2600288391113281,0.15411628936020844,10221.049613883595,clinical_study,0.33253983890090066,0.15504231283032063,https://www.globenewswire.com/news-release/2025/01/22/3013378/0/en/Elicio-Therapeutics-Reaches-Alignment-with-FDA-on-ELI-002-Registrational-Strategy.html
2025-01-22 08:00:00+00:00,pre_market,2025-01-22 09:30:00+00:00,2025-01-23 08:00:00+00:00,IMMP,LONG,428,1.909999966621399,1.929099966287613,1.929099966287613,1.900449966788292,True,False,8.174799857139595,0.9997505351646433,10229.224413740734,clinical_study,-4.9943050117358645,2.094245118395111,https://www.globenewswire.com/news-release/2025/01/22/3013446/0/en/Patient-Enrolment-Completed-for-EFTISARC-NEO-Phase-II-Trial.html
2025-01-22 08:00:00+00:00,pre_market,2025-01-22 09:30:00+00:00,2025-01-23 08:00:00+00:00,SCLX,LONG,1934,0.4230000078678131,0.4230000078678131,0.42723000794649124,0.42088500782847404,False,False,0.0,0.0,10229.224413740734,regulatory_filings,0.31253764542655915,0.0,https://www.globenewswire.com/news-release/2025/01/22/3013439/0/en/Scilex-Holding-Company-Announces-that-the-U-S-FDA-Has-Acknowledged-the-Submission-of-Our-Supplemental-New-Drug-Application-for-ELYXYB-in-Acute-Pain-Indication.html
2025-01-22 11:45:00+00:00,regular_market,2025-01-22 11:50:00+00:00,2025-01-22 15:18:00+00:00,VALN,LONG,174,4.679999828338623,4.65659982919693,4.72679982662201,4.65659982919693,False,True,-4.071599850654639,-0.4975450344487178,10225.15281389008,clinical_study,4.1198241218113445,-1.0683699942667462,https://www.globenewswire.com/news-release/2025/01/22/3013729/0/fr/Valneva-annonce-des-r%C3%A9sultats-de-Phase-2-positifs-chez-les-enfants-pour-son-vaccin-contre-le-chikungunya-ainsi-que-la-dose-s%C3%A9lectionn%C3%A9e-pour-la-Phase-3.html
2025-01-22 11:45:00+00:00,regular_market,2025-01-22 11:50:00+00:00,2025-01-22 15:18:00+00:00,VALN,LONG,174,4.679999828338623,4.65659982919693,4.72679982662201,4.65659982919693,False,True,-4.071599850654639,-0.49774315415654297,10221.081214039425,clinical_study,3.884639433603636,-1.0683699942667462,https://www.globenewswire.com/news-release/2025/01/22/3013729/0/en/Valneva-Reports-Positive-Phase-2-Results-in-Children-for-its-Chikungunya-Vaccine-and-Announces-Phase-3-Dose-Decision.html
2025-01-23 07:05:00+00:00,pre_market,2025-01-23 09:30:00+00:00,2025-01-24 07:05:00+00:00,KBLB,LONG,9085,0.09000000357627869,0.09090000361204148,0.09090000361204148,0.08955000355839729,True,False,8.176500324904978,0.9999554051182398,10229.25771436433,licensing_agreements,1.1932424317379224,11.111108351636926,https://www.globenewswire.com/news-release/2025/01/23/3014154/0/en/Kraig-Biocraft-Laboratories-Secures-New-Investment-License-Allowing-for-Further-Production-Scale-Up.html
2025-01-23 08:54:00+00:00,pre_market,2025-01-23 09:30:00+00:00,2025-01-24 08:54:00+00:00,TLSA,LONG,1022,0.800000011920929,0.800000011920929,0.8080000120401383,0.7960000118613243,False,False,0.0,0.0,10229.25771436433,clinical_study,2.020450093267757,0.0,https://www.globenewswire.com/news-release/2025/01/23/3014295/0/en/Tiziana-Life-Sciences-not-to-engage-in-capital-raising-activities-for-the-immediate-future.html
2025-01-23 15:00:00+00:00,regular_market,2025-01-23 15:05:00+00:00,2025-01-23 15:06:00+00:00,TLSA,LONG,1109,0.7378000020980835,0.7341110020875931,0.7451780021190644,0.7341110020875931,False,True,-4.0911010116338975,-0.49992642744363197,10225.166613352696,clinical_study,6.578201701446786,20.628894438057785,https://www.globenewswire.com/news-release/2025/01/23/3014558/0/en/Tiziana-Life-Sciences-Announces-Positive-Results-in-Treating-Spinal-Cord-Injury-With-Nasal-Anti-CD3.html
2025-01-24 07:36:00+00:00,pre_market,2025-01-24 09:30:00+00:00,2025-01-25 07:36:00+00:00,XFOR,LONG,1579,0.5180000066757202,0.5199999809265137,0.5231800067424774,0.5154100066423416,False,False,3.1579593420028687,0.386052308658594,10228.324572694699,clinical_study,-1.3648114458923128,0.38609541023529104,https://www.globenewswire.com/news-release/2025/01/24/3014855/0/en/X4-Pharmaceuticals-Announces-EMA-Validation-of-Marketing-Authorization-Application-MAA-for-Mavorixafor-for-the-Treatment-of-WHIM-Syndrome.html
